Nuclear receptor 4A1 (NR4A1) as a drug target for renal cell adenocarcinoma

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Hedrick, Erik ^a   Lee, Syng Ook ^b   Kim, Gyungeun ^c   Abdelrahim, Maen ^d   Jin, Un Ho ^a,c   Safe, Stephen ^a,c   Abudayyeh, Ala ^e  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Keimyung University   (South Korea)

^c Centre for Translational Cancer Research IBT Texas A and M HSC   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METHANE; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR NUR77 ANTAGONIST; OLIGONUCLEOTIDE; PROTEIN BCL 2; PROTEIN INHIBITOR; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; NR4A1 PROTEIN, HUMAN;

786 O CELL LINE; ACHN CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; GENE; GENE TARGETING; HUMAN; HUMAN CELL; IDH1 GENE; INFANT; KIDNEY CARCINOMA; KIDNEY CELL; MALE; MOUSE; NONHUMAN; NR4A1 GENE; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENAL CELL ADENOCARCINOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION; TXNDC5 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; KIDNEY NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; OLIGONUCLEOTIDES, ANTISENSE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934944167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128308     Document Type: Article

References (43)

1. Motzer RJ, Bander NH and Nanus DM. Renal-cell carcinoma. New England Journal of Medicine. 1996;335:865-875. PMID: 8778606
2. Motzer RJ, Russo P, Nanus DM and Berg WJ. Renal cell carcinoma. Current Problems in Cancer. 1997;21:185-232. PMID: 9285186
3. Cohen HT and McGovern FJ. Renal-cell carcinoma. New England Journal of Medicine. 2005;353:2477-2490. PMID: 16339096
4. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014;64:9-29. doi: 10.3322/caac.21208 PMID: 24399786
5. Yoshimura K and Uemura H. Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. International Journal of Urology. 2013;20:744-755. doi: 10.1111/iju.12147 PMID: 23521119
6. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. New England Journal of Medicine. 1998;338:1272-1278. PMID: 9562581
7. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005: CD001425.
8. Jantzer P and Schendel DJ. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Research. 1998;58:3078-3086. PMID: 9679974
9. Abe H and Kamai T. Recent advances in the treatment of metastatic renal cell carcinoma. International Journal of Urology. 2013;20:944-955. doi: 10.1111/iju.12187 PMID: 23692504
10. Escudier B, Szczylik C, Porta C and Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature Reviews: Clinical Oncology. 2012;9:327-337. doi: 10.1038/nrclinonc.2012.59 PMID: 22473096
11. Fishman MN. Targeted therapy of kidney cancer: keeping the art around the algorithms. Cancer Control. 2013;20:222-232. PMID: 23811706
12. Mattei J, Da Silva RD, Sehrt D, Molina WR and Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Letters. 2014;343:156-160. doi: 10.1016/j.canlet.2013.09.038 PMID: 24239667
13. Mittal K and Rini B. Kidney cancer in 2012: new frontiers in kidney cancer research. Nat Rev Urol. 2013;10:70-72. doi: 10.1038/nrurol.2012.256 PMID: 23318364
14. Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K, et al. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Research. 2010;70:6824-6836. doi: 10.1158/0008-5472. CAN-10-1992 PMID: 20660371
15. Lee SO, Andey T, Jin UH, Kim K, Singh M and Safe S. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Oncogene. 2012;31:3265-3276. doi: 10.1038/onc.2011.504 PMID: 22081070
16. Lee SO, Jin UH, Kang JH, Kim SB, Guthrie AS, Sreevalsan S, et al. The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells. Molecular Cancer Research. 2014;12:527-538. doi: 10.1158/1541-7786. MCR-13-0567 PMID: 24515801
17. Lee SO, Li X, Hedrick E, Jin UH, Tjalkens RB, Backos DS, et al. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells. Molecular Endocrinology. 2014;28:1729-1739. doi: 10.1210/me.2014-1102 PMID: 25099012
18. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science. 2000;289:1159-1164. PMID: 10947977
19. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116:527-540. PMID: 14980220
20. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell. 2008;14:285-298. doi: 10.1016/j.ccr.2008.09.002 PMID: 18835031
21. Zhao BX, Chen HZ, Lei NZ, Li GD, Zhao WX, Zhan YY, et al. p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO Journal. 2006;25:5703-5715. PMID: 17139261
22. Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, et al. Identification of a novel stressresponsive gene Hi95 involved in regulation of cell viability. Oncogene. 2002;21:6017-6031. PMID: 12203114
23. Maxwell MA and Muscat GE. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal. 2006;4:e002. PMID: 16604165
24. Pearen MA and Muscat GE. Minireview: Nuclear hormone receptor 4A signaling: implications for metabolic disease. Molecular Endocrinology. 2010;24:1891-1903. doi: 10.1210/me.2010-0015 PMID: 20392876
25. Zhang XK. Targeting Nur77 translocation. Expert Opinion on Therapeutic Targets. 2007;11:69-79. PMID: 17150035
26. Lee SO, Li X, Khan S and Safe S. Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opinion on Therapeutic Targets. 2011;15:195-206. doi: 10.1517/14728222.2011.547481 PMID: 21204731
27. Safe S, Jin UH, Hedrick E, Reeder A and Lee SO. Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Molecular Endocrinology. 2014;28:157-172. doi: 10.1210/me.2013-1291 PMID: 24295738
28. Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Research. 2009;69:6906-6914. doi: 10.1158/0008-5472. CAN-09-0540 PMID: 19671798
29. Zhan Y, Du X, Chen H, Liu J, Zhao B, Huang D, et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nature Chemical Biology. 2008;4:548-556. doi: 10.1038/nchembio.106 PMID: 18690216
30. Liu JJ, Zeng HN, Zhang LR, Zhan YY, Chen Y, Wang Y, et al. A unique pharmacophore for activation of the nuclear orphan receptor Nur77 in vivo and in vitro. Cancer Research. 2010;70:3628-3637. doi: 10. 1158/0008-5472. CAN-09-3160 PMID: 20388790
31. Zhan YY, Chen Y, Zhang Q, Zhuang JJ, Tian M, Chen HZ, et al. The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nature Chemical Biology. 2012;8:897-904. doi: 10. 1038/nchembio.1069 PMID: 22983157
32. Wang WJ, Wang Y, Chen HZ, Xing YZ, Li FW, Zhang Q, et al. Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway. Nature Chemical Biology. 2014;10:133-140. doi: 10.1038/nchembio.1406 PMID: 24316735
33. Hayashi K, Ohkura N, Miki K, Osada S and Tomino Y. Early induction of the NGFI-B/Nur77 family genes in nephritis induced by anti-glomerular basement membrane antibody. Molecular and Cellular Endocrinology. 1996;123:205-209. PMID: 8961258
34. Balasubramanian S, Jansen M, Valerius MT, Humphreys BD and Strom TB. Orphan nuclear receptor Nur77 promotes acute kidney injury and renal epithelial apoptosis. Journal of the American Society of Nephrology. 2012;23:674-686. doi: 10.1681/ASN.2011070646 PMID: 22343121
35. Choi JW, Park SC, Kang GH, Liu JO and Youn HD. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Cancer Research. 2004;64:35-39. PMID: 14729605
36. Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, et al. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology. 2007;69:843-848. PMID: 17482919
37. Okamura K, Koike H, Sekine Y, Matsui H and Suzuki K. Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiology. 2009;33:137-141. doi: 10.1016/j.canep. 2009.06.005 PMID: 19679061
38. Lei Y, Geng Z, Guo-Jun. W, He Wand Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Molecular and Cellular Biochemistry. 2010;344:23-31. doi: 10.1007/s11010-010-0525-3 PMID: 20563741
39. Dordevic G, Matusan Ilijas K, Hadzisejdic I, Maricic A, Grahovac B and Jonjic N. EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma. Journal of Biomedical Science. 2012;19:40. doi: 10.1186/1423-0127-19-40 PMID: 22475688
40. Li X, Zhang Z, Xin D, Chua CW, Wong YC, Leung SC, et al. Prognostic significance of Id-1 and its association with EGFR in renal cell cancer. Histopathology. 2007;50:484-490. PMID: 17448024
41. Matusan-Ilijas K, Damante G, Fabbro D, Dordevic G, Hadzisejdic I, Grahovac M, et al. EGFR expression is linked to osteopontin and Nf-kappaB signaling in clear cell renal cell carcinoma. Clinical & Translational Oncology. 2013;15:65-71. doi: 10.1007/s12094-012-0889-9 PMID: 22855173
42. Hirai Y, Kawabe N, Tsuda Y, Miyamoto S and Iwakawa S. Effect of 2-methoxyestradiol, buthionine sulfoximine and hydrogen peroxide on the viability of renal carcinoma cell lines (ACHN and ACVB). Biological and Pharmaceutical Bulletin. 2006;29:1064-1067. PMID: 16651749
43. Sourbier C, Valera-Romero V, Giubellino A, Yang Y, Sudarshan S, Neckers L, et al. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle. 2010;9:4183-4189. PMID: 20953139